NCT01837927View on ClinicalTrials.gov

Efficacy of NVA237 (50 μg o.d) Using Tiotropium (5μg μg o.d) as Active Control in COPD Patients.

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

NVA237

Once daily for 52 weeks

DRUG

Tiotropium Respimat®

Once daily for 52 weeks

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY